Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study

SIMPLE SUMMARY: The advent of immune checkpoint inhibitors (ICI) improved the prognosis for patients with advanced melanoma. However, many patients do not benefit from ICI therapy due to primary and acquired resistance. Observations in murine systems suggested that coagulation factor Xa impedes anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Haist, Maximilian, Stege, Henner, Pemler, Saskia, Heinz, Jaqueline, Fleischer, Maria Isabel, Graf, Claudine, Ruf, Wolfram, Loquai, Carmen, Grabbe, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534137/
https://www.ncbi.nlm.nih.gov/pubmed/34680252
http://dx.doi.org/10.3390/cancers13205103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534137/
https://www.ncbi.nlm.nih.gov/pubmed/34680252
http://dx.doi.org/10.3390/cancers13205103

Ejemplares similares